Literature DB >> 21040215

Selection and analysis of anti-cancer antibodies for cancer therapy obtained from antibody phage library.

Gene Kurosawa1, Mariko Sumitomo, Yoshinori Ukai, Juvy Subere, Chiho Muramatsu, Keiko Eguchi, Miho Tanaka-Hashiba, Mai Sugiura, Misaki Ando, Noriko Sato, Miwa Morita, Kazuki Inaba, Satoko Morigaki, Akihiko Takasaki, Yasushi Akahori, Shuichi Miyakawa, Ichiro Uyama, Koutarou Maeda, Ryoichi Shiroki, Kiyotaka Hoshinaga, Yoshikazu Mizoguchi, Yoshinobu Hattori, Atsushi Sugioka, Mototaka Sugiura, Yoshikazu Kurosawa.   

Abstract

The search for effective antibodies (Ab) for curable cancer immunotherapy has been a quest of many research groups in order to find an effective target that exists on the cancer cell surface. So far there have been no conclusive answers to shed light on the search. This study therefore aimed to bridge the gap of cancer therapy. Screening against 49 kinds of cell lines belonging to 11 kinds of solids cancers was performed. Isolation and characterization for approximately 4200 monoclonal antibodies (mAb) was also performed thereafter. Of those mAb 488 clones that turned out to bind to 29 tumor-associated antigens (TAA) were subjected to immunohistochemical (IHC) analyses. Selection of target antigens (Ag) and a potential antibody for cancer therapy was conducted prior to clinical examinations. In order to find predictably effective targets for therapeutic Ab against solid cancers, expression of the Ag on the surface of cancer and normal cells was extensively examined by IHC analyses using fresh cancer specimens resected from patients. In this study, the tendencies of all staining patterns and distribution of the Ab are reported. While all of the TAA appeared to be involved in tumorigenesis, their expression was not restricted to some specific tumor types but rather randomly distributed among various cancers. Some kinds of Ab including anti-epidermal growth factor receptor (EGFR) and anti-human epidermal growth factor receptor 2 (HER2) indicated the frequency of expression in normal cells was generally low. We concluded that identification of 488 mAb and the accumulated results of IHC analyses in this study could be the key for further therapeutic Ab against cancers. The targets that showed cancer-specific expression are expected to be better for therapeutic Ab than the other Ab. Moreover, further investigation into the growth of cancer cell lines using full human IgG form of Ab shows available efficacy in specific cases.
© 2010 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21040215     DOI: 10.1111/j.1349-7006.2010.01739.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  7 in total

1.  A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies.

Authors:  David T Dudley; Xiao-Yan Li; Casey Y Hu; Celina G Kleer; Amanda L Willis; Stephen J Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

2.  In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study.

Authors:  Fukiko Hihara; Hiroki Matsumoto; Mitsuyoshi Yoshimoto; Takashi Masuko; Yuichi Endo; Chika Igarashi; Tomoko Tachibana; Mitsuhiro Shinada; Ming-Rong Zhang; Gene Kurosawa; Aya Sugyo; Atsushi B Tsuji; Tatsuya Higashi; Hiroaki Kurihara; Makoto Ueno; Yukie Yoshii
Journal:  Int J Mol Sci       Date:  2022-05-22       Impact factor: 6.208

3.  Classification of 27 Tumor-Associated Antigens by Histochemical Analysis of 36 Freshly Resected Lung Cancer Tissues.

Authors:  Gene Kurosawa; Mototaka Sugiura; Yoshinobu Hattori; Hiroyuki Tsuda; Yoshikazu Kurosawa
Journal:  Int J Mol Sci       Date:  2016-11-08       Impact factor: 5.923

Review 4.  Antibody-Based Approaches to Target Pancreatic Tumours.

Authors:  Marie Sorbara; Pierre Cordelier; Nicolas Bery
Journal:  Antibodies (Basel)       Date:  2022-07-12

5.  Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.

Authors:  Aya Sugyo; Atsushi B Tsuji; Hitomi Sudo; Kotaro Nagatsu; Mitsuru Koizumi; Yoshinori Ukai; Gene Kurosawa; Ming-Rong Zhang; Yoshikazu Kurosawa; Tsuneo Saga
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

6.  Development of a complete human anti-human transferrin receptor C antibody as a novel marker of oral dysplasia and oral cancer.

Authors:  Kentaro Nagai; Shingo Nakahata; Shunsuke Shimosaki; Tomohiro Tamura; Yuudai Kondo; Takashi Baba; Tomohiko Taki; Masafumi Taniwaki; Gene Kurosawa; Yukio Sudo; Seiji Okada; Sumio Sakoda; Kazuhiro Morishita
Journal:  Cancer Med       Date:  2014-06-02       Impact factor: 4.452

7.  Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression.

Authors:  Hitomi Sudo; Atsushi B Tsuji; Aya Sugyo; Gene Kurosawa; Yoshikazu Kurosawa; David Alexander; Hiroyuki Tsuda; Tsuneo Saga; Tatsuya Higashi
Journal:  Int J Mol Sci       Date:  2020-03-26       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.